ArticleBMC pharmacology & toxicology2026
The anticancer properties of the nanocomposite of low-nanoscale Ag nanoparticles obtained in SiO
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsSilver-based nanomedicine is an ongoing trend in anticancer research. Polymers greatly improve the stability of bare metal silver and improve its interaction with cells. We aimed to evaluate the anticancer efficiency of the synthesized Ag/polymer nanocomposite against B95-8 and Wish cell lines.
methodsA highly stable low-nanoscale Ag/silica-grafted polyacrylamide nanocomposite (Ag/Hyb) with a mean particle size of 6 nm, estimated by TEM, was obtained. Malignant cell lines: B95-8 (Burkitt lymphoma), Wish (human amniotic with marker chromosomes of HeLa), and the control MDCK cell lines were used. To assess cell viability, the MTT test was applied. To find putative targets of Ag/Hyb, mitochondrial respiration, lipid peroxidation, and NO synthase activity were evaluated in rat tissue homogenates.
resultsThe half-inhibition (IC50) of B95-8 and Wish cells viability was 6.1 and 7.8 µg/ml, respectively, and was not reached in the control MDCK cells, which indicated high anticancer activity. At the same dilutions, the matrix was similarly toxic to B95-8 cells but safe to Wish and MDCK cells. Dose-dependent suppression of glutamate-driven respiration, strong NO synthases (NOS) stimulation, and the reduction of lipid peroxidation (LPO) within the same concentration range were observed. The correlation was found between NOS activation and mitochondrial CI suppression, which indicated possible involvement of these processes in cytotoxicity mechanisms of Ag/Hyb.
conclusionsA low-nanoscale Ag/SiO2-g-PAAm nanocomposite with high anticancer activity in vitro in a low micromolar concentration range was obtained. The putative mechanism of Ag/Hyb action was proposed, in which Complex I and NOS activity could be involved in anticancer effects. Based on the experiments, we came to the conclusion that Ag/Hyb is a promising system for the future design of anticancer preparations; however, molecular mechanisms of Ag/Hyb action in different cancer cell types require detailed study in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.